Literature DB >> 18393906

Medical treatment for neurocysticercosis: drugs, indications and perspectives.

Helgi Jung1, Graciela Cárdenas, Edda Sciutto, Agnes Fleury.   

Abstract

Neurocysticercosis is one of the most frequent parasitic diseases affecting the central nervous system. The introduction of anticysticidal therapy in the early 80's and the concomitant improvement of the radiological techniques have lead to apparently significant progress in patient prognosis. However, due to the specificity of the disease, a great debate has been generated on the real usefulness of cysticidal drugs. This article revises and discusses the pharmacological aspects of cysticidal treatment and summarizes current indications for the different types of the disease.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18393906     DOI: 10.2174/156802608783790811

Source DB:  PubMed          Journal:  Curr Top Med Chem        ISSN: 1568-0266            Impact factor:   3.295


  4 in total

1.  Subarachnoidal Neurocysticercosis non-responsive to cysticidal drugs: a case series.

Authors:  Graciela Cárdenas; Roger Carrillo-Mezo; Helgi Jung; Edda Sciutto; Jose Luis Soto Hernandez; Agnès Fleury
Journal:  BMC Neurol       Date:  2010-03-04       Impact factor: 2.474

2.  Commentary.

Authors:  Agnès Fleury
Journal:  J Neurosci Rural Pract       Date:  2013-01

3.  (S)-(+)-cis-4'-Benzyl-oxypraziquantel.

Authors:  Alberto Cedillo-Cruz; María Isabel Aguilar; Helgi Jung-Cook
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2013-11-30

4.  New diagnostic criteria for neurocysticercosis: Reliability and validity.

Authors:  Arturo Carpio; Agnès Fleury; Matthew L Romo; Ronaldo Abraham; Jaime Fandiño; Juan C Durán; Graciela Cárdenas; Jorge Moncayo; Cleonísio Leite Rodrigues; Daniel San-Juan; Marcos Serrano-Dueñas; Oswaldo Takayanagui; Josemir W Sander
Journal:  Ann Neurol       Date:  2016-08-13       Impact factor: 10.422

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.